Posted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status on the formularies of Alberta, New Brunswick, Ontario, Quebec and Saskatchewan for the treatment of adults with rheumatoid arthritis and psoriatic arthritis.
In addition, Rinvoq is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits program (NIHB)6 for the treatment of rheumatoid arthritis and psoriatic arthritis.
